Amrut Ambardekar
Concepts (422)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart-Assist Devices | 37 | 2024 | 539 | 8.350 |
Why?
| Heart Failure | 51 | 2024 | 2150 | 6.310 |
Why?
| Heart Transplantation | 24 | 2024 | 721 | 4.940 |
Why?
| Amyloidosis | 4 | 2023 | 42 | 1.820 |
Why?
| Cardiomyopathies | 9 | 2025 | 340 | 1.750 |
Why?
| Heart Ventricles | 9 | 2020 | 781 | 1.600 |
Why?
| Cardiomyopathy, Dilated | 9 | 2020 | 381 | 1.110 |
Why?
| Ventricular Dysfunction, Left | 8 | 2023 | 385 | 1.070 |
Why?
| Cardiomyopathy, Hypertrophic | 2 | 2024 | 132 | 0.980 |
Why?
| Myocardium | 10 | 2023 | 980 | 0.950 |
Why?
| Arrhythmias, Cardiac | 6 | 2022 | 317 | 0.870 |
Why?
| Ventricular Dysfunction, Right | 3 | 2020 | 231 | 0.840 |
Why?
| Myocytes, Cardiac | 11 | 2023 | 499 | 0.840 |
Why?
| Humans | 101 | 2025 | 129650 | 0.840 |
Why?
| Defibrillators, Implantable | 4 | 2020 | 300 | 0.820 |
Why?
| Rejuvenation | 1 | 2022 | 18 | 0.790 |
Why?
| Assisted Circulation | 2 | 2021 | 26 | 0.770 |
Why?
| Aortic Valve Insufficiency | 1 | 2022 | 46 | 0.760 |
Why?
| Transplant Recipients | 4 | 2021 | 162 | 0.760 |
Why?
| Fibrosis | 5 | 2022 | 520 | 0.750 |
Why?
| Echocardiography | 7 | 2017 | 629 | 0.740 |
Why?
| Hemodynamics | 7 | 2023 | 1090 | 0.730 |
Why?
| Stroke Volume | 9 | 2024 | 592 | 0.730 |
Why?
| Vascular Stiffness | 2 | 2017 | 467 | 0.710 |
Why?
| Calcineurin Inhibitors | 1 | 2021 | 68 | 0.700 |
Why?
| Giant Cells | 1 | 2020 | 23 | 0.700 |
Why?
| Arteries | 1 | 2022 | 265 | 0.680 |
Why?
| Aortic Diseases | 1 | 2021 | 115 | 0.680 |
Why?
| Heart Neoplasms | 1 | 2020 | 50 | 0.670 |
Why?
| Immunosuppressive Agents | 5 | 2021 | 853 | 0.670 |
Why?
| Ventricular Function, Left | 7 | 2023 | 527 | 0.670 |
Why?
| Sarcoma, Kaposi | 1 | 2020 | 76 | 0.660 |
Why?
| Coronary Vessels | 2 | 2018 | 241 | 0.640 |
Why?
| Myocarditis | 1 | 2020 | 98 | 0.640 |
Why?
| Ventricular Function, Right | 4 | 2020 | 276 | 0.630 |
Why?
| Middle Aged | 36 | 2025 | 31154 | 0.620 |
Why?
| Brugada Syndrome | 2 | 2009 | 9 | 0.600 |
Why?
| Myocardial Contraction | 4 | 2020 | 335 | 0.600 |
Why?
| Graft Rejection | 3 | 2021 | 598 | 0.600 |
Why?
| Heart | 6 | 2023 | 637 | 0.580 |
Why?
| Bariatric Surgery | 1 | 2021 | 193 | 0.570 |
Why?
| Extracellular Matrix | 1 | 2021 | 504 | 0.560 |
Why?
| Male | 48 | 2025 | 63681 | 0.560 |
Why?
| Ventricular Remodeling | 3 | 2021 | 255 | 0.530 |
Why?
| Myocardial Ischemia | 4 | 2019 | 258 | 0.530 |
Why?
| Female | 48 | 2025 | 68776 | 0.510 |
Why?
| Cryosurgery | 1 | 2016 | 57 | 0.490 |
Why?
| Thrombosis | 2 | 2016 | 343 | 0.480 |
Why?
| Heart Rate | 2 | 2021 | 802 | 0.470 |
Why?
| Amyloid Neuropathies, Familial | 2 | 2025 | 14 | 0.470 |
Why?
| Surgical Procedures, Operative | 1 | 2017 | 244 | 0.450 |
Why?
| Aged | 22 | 2025 | 22103 | 0.450 |
Why?
| Tachycardia, Ventricular | 1 | 2016 | 167 | 0.450 |
Why?
| Blood Pressure | 5 | 2022 | 1736 | 0.430 |
Why?
| Electrocardiography | 4 | 2020 | 608 | 0.430 |
Why?
| Marijuana Abuse | 1 | 2016 | 234 | 0.420 |
Why?
| Treatment Outcome | 13 | 2024 | 10230 | 0.410 |
Why?
| Aorta, Thoracic | 1 | 2015 | 262 | 0.400 |
Why?
| Physician-Patient Relations | 1 | 2017 | 539 | 0.400 |
Why?
| Myofibrils | 3 | 2022 | 49 | 0.400 |
Why?
| Patient-Centered Care | 2 | 2021 | 505 | 0.390 |
Why?
| Guideline Adherence | 3 | 2011 | 526 | 0.370 |
Why?
| Adult | 21 | 2023 | 35576 | 0.360 |
Why?
| Patient Compliance | 2 | 2017 | 565 | 0.350 |
Why?
| Cardiology | 2 | 2023 | 261 | 0.350 |
Why?
| Prealbumin | 3 | 2025 | 28 | 0.340 |
Why?
| Recovery of Function | 2 | 2011 | 642 | 0.340 |
Why?
| Cardiac Tamponade | 1 | 2010 | 14 | 0.330 |
Why?
| Risk Assessment | 6 | 2021 | 3240 | 0.330 |
Why?
| Hospitals, Rural | 1 | 2009 | 37 | 0.330 |
Why?
| Baroreflex | 2 | 2021 | 53 | 0.330 |
Why?
| RNA, Long Noncoding | 2 | 2022 | 179 | 0.320 |
Why?
| Calcium | 4 | 2023 | 1213 | 0.320 |
Why?
| Sarcomeres | 3 | 2022 | 92 | 0.320 |
Why?
| Cardiac Output | 3 | 2023 | 156 | 0.320 |
Why?
| Safety | 1 | 2011 | 331 | 0.320 |
Why?
| Cannabis | 1 | 2016 | 465 | 0.320 |
Why?
| Automobile Driving | 1 | 2011 | 140 | 0.320 |
Why?
| Electric Stimulation Therapy | 1 | 2010 | 77 | 0.310 |
Why?
| Hospitals, Urban | 1 | 2009 | 129 | 0.310 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2023 | 2441 | 0.310 |
Why?
| Cardiac Pacing, Artificial | 1 | 2009 | 85 | 0.310 |
Why?
| Registries | 6 | 2021 | 1896 | 0.310 |
Why?
| Pulsatile Flow | 2 | 2018 | 59 | 0.300 |
Why?
| Mineralocorticoid Receptor Antagonists | 2 | 2023 | 46 | 0.290 |
Why?
| Mastitis | 1 | 2007 | 4 | 0.290 |
Why?
| Vascular Remodeling | 2 | 2021 | 192 | 0.290 |
Why?
| Counseling | 1 | 2011 | 385 | 0.290 |
Why?
| Puerperal Disorders | 1 | 2007 | 30 | 0.280 |
Why?
| Diagnosis, Differential | 4 | 2019 | 1434 | 0.280 |
Why?
| Quality Assurance, Health Care | 1 | 2009 | 318 | 0.280 |
Why?
| Length of Stay | 2 | 2009 | 1127 | 0.280 |
Why?
| Coronary Disease | 1 | 2009 | 385 | 0.270 |
Why?
| Environment | 1 | 2009 | 343 | 0.270 |
Why?
| Prospective Studies | 10 | 2021 | 7133 | 0.270 |
Why?
| Retrospective Studies | 13 | 2023 | 14518 | 0.260 |
Why?
| Follow-Up Studies | 6 | 2021 | 4897 | 0.250 |
Why?
| Diastole | 2 | 2018 | 148 | 0.250 |
Why?
| HIV Infections | 1 | 2020 | 2720 | 0.250 |
Why?
| Troponin I | 2 | 2019 | 75 | 0.240 |
Why?
| Inpatients | 1 | 2009 | 467 | 0.240 |
Why?
| Quality of Health Care | 1 | 2009 | 608 | 0.230 |
Why?
| Heart Failure, Systolic | 2 | 2024 | 25 | 0.230 |
Why?
| Perioperative Care | 2 | 2017 | 152 | 0.220 |
Why?
| Quality of Life | 6 | 2024 | 2704 | 0.220 |
Why?
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2023 | 10 | 0.210 |
Why?
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 37 | 0.210 |
Why?
| Preoperative Care | 2 | 2017 | 340 | 0.200 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2021 | 2073 | 0.200 |
Why?
| Heart Injuries | 1 | 2023 | 36 | 0.200 |
Why?
| Patient Transfer | 2 | 2019 | 162 | 0.200 |
Why?
| MicroRNAs | 2 | 2022 | 678 | 0.200 |
Why?
| Mitochondrial Membrane Transport Proteins | 1 | 2022 | 43 | 0.200 |
Why?
| Angiotensin Receptor Antagonists | 1 | 2023 | 89 | 0.200 |
Why?
| Hospitalization | 4 | 2024 | 2070 | 0.200 |
Why?
| Metalloproteases | 1 | 2022 | 44 | 0.200 |
Why?
| Sequence Analysis, RNA | 2 | 2021 | 429 | 0.200 |
Why?
| Cohort Studies | 6 | 2023 | 5420 | 0.190 |
Why?
| Cadherin Related Proteins | 1 | 2022 | 12 | 0.190 |
Why?
| Triage | 1 | 2024 | 206 | 0.190 |
Why?
| Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.190 |
Why?
| Long Term Adverse Effects | 1 | 2021 | 12 | 0.190 |
Why?
| ADAMTS4 Protein | 1 | 2021 | 16 | 0.190 |
Why?
| Succinic Acid | 2 | 2019 | 39 | 0.190 |
Why?
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 16 | 0.180 |
Why?
| Leukopenia | 1 | 2021 | 28 | 0.180 |
Why?
| Cation Transport Proteins | 1 | 2022 | 132 | 0.180 |
Why?
| Calcium-Binding Proteins | 1 | 2022 | 210 | 0.180 |
Why?
| Cardiovascular System | 1 | 2023 | 137 | 0.180 |
Why?
| Prognosis | 5 | 2025 | 3794 | 0.180 |
Why?
| Pressoreceptors | 1 | 2021 | 19 | 0.180 |
Why?
| Carrier Proteins | 2 | 2022 | 743 | 0.180 |
Why?
| Muscle Proteins | 1 | 2022 | 220 | 0.170 |
Why?
| Case-Control Studies | 4 | 2022 | 3381 | 0.170 |
Why?
| Mycophenolic Acid | 1 | 2021 | 110 | 0.170 |
Why?
| Myocardial Infarction | 2 | 2023 | 1022 | 0.170 |
Why?
| Alternative Splicing | 1 | 2022 | 218 | 0.170 |
Why?
| Hypertension | 2 | 2020 | 1242 | 0.170 |
Why?
| Cell Adhesion | 2 | 2018 | 452 | 0.170 |
Why?
| Immunohistochemistry | 2 | 2021 | 1698 | 0.160 |
Why?
| Disease Progression | 2 | 2018 | 2635 | 0.160 |
Why?
| HIV | 1 | 2020 | 226 | 0.160 |
Why?
| Terminology as Topic | 1 | 2020 | 204 | 0.160 |
Why?
| Myocardial Reperfusion Injury | 1 | 2020 | 129 | 0.160 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 274 | 0.160 |
Why?
| Consensus | 4 | 2023 | 616 | 0.160 |
Why?
| Severity of Illness Index | 5 | 2021 | 2742 | 0.150 |
Why?
| Aortic Valve | 1 | 2022 | 348 | 0.150 |
Why?
| United States | 9 | 2023 | 13903 | 0.150 |
Why?
| Cell Culture Techniques | 1 | 2021 | 345 | 0.150 |
Why?
| Clinical Decision-Making | 2 | 2020 | 303 | 0.150 |
Why?
| Longitudinal Studies | 3 | 2016 | 2717 | 0.150 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2020 | 177 | 0.150 |
Why?
| Exercise Test | 4 | 2023 | 613 | 0.150 |
Why?
| Mice | 11 | 2023 | 16937 | 0.150 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 237 | 0.150 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2021 | 221 | 0.150 |
Why?
| Filamins | 1 | 2018 | 28 | 0.140 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2018 | 182 | 0.140 |
Why?
| Mitochondrial Proteins | 1 | 2019 | 248 | 0.140 |
Why?
| Recurrence | 1 | 2020 | 1007 | 0.140 |
Why?
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 12 | 0.140 |
Why?
| Mutation | 2 | 2018 | 3717 | 0.140 |
Why?
| Pilot Projects | 3 | 2019 | 1587 | 0.140 |
Why?
| Cerebrovascular Circulation | 1 | 2018 | 226 | 0.130 |
Why?
| Immunity, Cellular | 1 | 2018 | 265 | 0.130 |
Why?
| Caliciviridae Infections | 1 | 2016 | 17 | 0.130 |
Why?
| Anesthetics | 1 | 2017 | 66 | 0.130 |
Why?
| PTEN Phosphohydrolase | 1 | 2018 | 161 | 0.130 |
Why?
| Transcriptome | 2 | 2020 | 887 | 0.130 |
Why?
| ErbB Receptors | 1 | 2020 | 607 | 0.130 |
Why?
| Time Factors | 5 | 2024 | 6556 | 0.130 |
Why?
| Down-Regulation | 2 | 2016 | 636 | 0.130 |
Why?
| Brain | 2 | 2018 | 2679 | 0.130 |
Why?
| Self Care | 1 | 2019 | 370 | 0.130 |
Why?
| Polypharmacy | 1 | 2017 | 84 | 0.130 |
Why?
| Animals | 14 | 2023 | 35361 | 0.130 |
Why?
| Transition to Adult Care | 1 | 2017 | 79 | 0.130 |
Why?
| Histone Deacetylases | 1 | 2018 | 212 | 0.130 |
Why?
| Prosthesis Design | 3 | 2014 | 306 | 0.130 |
Why?
| Eligibility Determination | 1 | 2016 | 63 | 0.130 |
Why?
| Myocytes, Smooth Muscle | 1 | 2018 | 259 | 0.130 |
Why?
| Cell Differentiation | 2 | 2021 | 1902 | 0.130 |
Why?
| Clinical Trials as Topic | 1 | 2020 | 1004 | 0.120 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2020 | 511 | 0.120 |
Why?
| Nonprescription Drugs | 1 | 2016 | 66 | 0.120 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2016 | 87 | 0.120 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 399 | 0.120 |
Why?
| Drug Interactions | 1 | 2017 | 394 | 0.120 |
Why?
| Receptors, Adrenergic, beta-1 | 1 | 2015 | 46 | 0.120 |
Why?
| Positron-Emission Tomography | 1 | 2017 | 288 | 0.120 |
Why?
| Antiviral Agents | 1 | 2021 | 712 | 0.120 |
Why?
| Gene Expression Profiling | 2 | 2021 | 1706 | 0.120 |
Why?
| Postoperative Care | 1 | 2017 | 241 | 0.120 |
Why?
| Phosphorylation | 3 | 2019 | 1713 | 0.120 |
Why?
| Hospital Mortality | 2 | 2009 | 850 | 0.120 |
Why?
| Tacrolimus | 1 | 2016 | 193 | 0.120 |
Why?
| Proportional Hazards Models | 3 | 2020 | 1201 | 0.120 |
Why?
| Prescription Drugs | 1 | 2016 | 112 | 0.120 |
Why?
| Viscosity | 1 | 2015 | 90 | 0.120 |
Why?
| Partial Thromboplastin Time | 1 | 2014 | 52 | 0.110 |
Why?
| Hypoglycemic Agents | 1 | 2023 | 1220 | 0.110 |
Why?
| Health Status | 1 | 2019 | 755 | 0.110 |
Why?
| Elastic Modulus | 1 | 2015 | 123 | 0.110 |
Why?
| Cardiovascular Agents | 2 | 2020 | 156 | 0.110 |
Why?
| Biomarkers | 3 | 2023 | 3973 | 0.110 |
Why?
| Coronary Artery Disease | 1 | 2020 | 679 | 0.110 |
Why?
| Rats | 5 | 2022 | 5500 | 0.110 |
Why?
| Attitude to Health | 1 | 2017 | 431 | 0.110 |
Why?
| Ambulatory Care | 1 | 2017 | 504 | 0.110 |
Why?
| Hip Prosthesis | 1 | 2014 | 37 | 0.110 |
Why?
| Systole | 1 | 2014 | 191 | 0.110 |
Why?
| Atherosclerosis | 1 | 2018 | 402 | 0.110 |
Why?
| Vaccination | 1 | 2022 | 1348 | 0.110 |
Why?
| Incidence | 3 | 2019 | 2644 | 0.110 |
Why?
| Patient Selection | 2 | 2017 | 663 | 0.110 |
Why?
| Transcription, Genetic | 1 | 2020 | 1418 | 0.110 |
Why?
| Shock, Cardiogenic | 1 | 2014 | 60 | 0.110 |
Why?
| Prosthesis Failure | 1 | 2014 | 114 | 0.100 |
Why?
| Quality Improvement | 1 | 2021 | 1103 | 0.100 |
Why?
| Liver Transplantation | 1 | 2020 | 831 | 0.100 |
Why?
| Marijuana Smoking | 1 | 2016 | 247 | 0.100 |
Why?
| Blood Coagulation | 1 | 2014 | 238 | 0.100 |
Why?
| Patient Education as Topic | 1 | 2017 | 743 | 0.100 |
Why?
| Young Adult | 6 | 2019 | 12426 | 0.100 |
Why?
| Ventricular Premature Complexes | 1 | 2012 | 36 | 0.090 |
Why?
| Attitude of Health Personnel | 2 | 2017 | 1098 | 0.090 |
Why?
| Nuclear Proteins | 1 | 2016 | 663 | 0.090 |
Why?
| Reproducibility of Results | 2 | 2019 | 3083 | 0.090 |
Why?
| Natriuretic Peptides | 1 | 2011 | 9 | 0.090 |
Why?
| Biopsy | 1 | 2015 | 1097 | 0.090 |
Why?
| Risk Factors | 4 | 2020 | 9765 | 0.090 |
Why?
| Kaplan-Meier Estimate | 2 | 2010 | 857 | 0.090 |
Why?
| Neurotransmitter Agents | 1 | 2011 | 81 | 0.090 |
Why?
| Decision Making | 1 | 2017 | 851 | 0.090 |
Why?
| Transforming Growth Factor beta1 | 2 | 2022 | 157 | 0.090 |
Why?
| Connectin | 2 | 2022 | 31 | 0.090 |
Why?
| Stroke | 1 | 2019 | 1071 | 0.090 |
Why?
| Gene Expression Regulation | 3 | 2020 | 2548 | 0.080 |
Why?
| Endpoint Determination | 2 | 2020 | 76 | 0.080 |
Why?
| Receptors, Adrenergic, beta | 1 | 2011 | 127 | 0.080 |
Why?
| Task Performance and Analysis | 1 | 2011 | 173 | 0.080 |
Why?
| Sensitivity and Specificity | 1 | 2015 | 1838 | 0.080 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 198 | 0.080 |
Why?
| Pericardial Effusion | 1 | 2010 | 21 | 0.080 |
Why?
| Extracellular Matrix Proteins | 1 | 2011 | 144 | 0.080 |
Why?
| Anticoagulants | 1 | 2014 | 637 | 0.080 |
Why?
| Heart Septum | 1 | 2009 | 27 | 0.080 |
Why?
| Comorbidity | 2 | 2020 | 1547 | 0.080 |
Why?
| Myocardial Revascularization | 1 | 2009 | 72 | 0.080 |
Why?
| DNA | 1 | 2016 | 1400 | 0.080 |
Why?
| Cells, Cultured | 3 | 2022 | 4083 | 0.080 |
Why?
| Exercise | 1 | 2020 | 1925 | 0.080 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 1279 | 0.080 |
Why?
| Adrenergic beta-Antagonists | 1 | 2011 | 321 | 0.080 |
Why?
| Ultrasonography | 1 | 2012 | 716 | 0.080 |
Why?
| Disease Models, Animal | 4 | 2022 | 4063 | 0.080 |
Why?
| Europe | 2 | 2020 | 364 | 0.080 |
Why?
| Transcription Factors | 1 | 2016 | 1651 | 0.070 |
Why?
| Coronary Circulation | 1 | 2008 | 138 | 0.070 |
Why?
| Syndrome | 1 | 2008 | 341 | 0.070 |
Why?
| Cardiac Catheterization | 2 | 2020 | 518 | 0.070 |
Why?
| Body Temperature | 1 | 2007 | 212 | 0.070 |
Why?
| Evidence-Based Medicine | 1 | 2011 | 718 | 0.070 |
Why?
| Blood Flow Velocity | 1 | 2008 | 404 | 0.070 |
Why?
| Continuity of Patient Care | 1 | 2009 | 275 | 0.070 |
Why?
| Delivery of Health Care | 2 | 2023 | 894 | 0.060 |
Why?
| Genetic Predisposition to Disease | 3 | 2020 | 2282 | 0.060 |
Why?
| Survivors | 1 | 2009 | 464 | 0.060 |
Why?
| Kidney Diseases | 1 | 2009 | 384 | 0.060 |
Why?
| Clinical Protocols | 2 | 2017 | 255 | 0.060 |
Why?
| Mice, Knockout | 2 | 2022 | 2871 | 0.060 |
Why?
| Practice Guidelines as Topic | 2 | 2009 | 1501 | 0.060 |
Why?
| Benzoxazoles | 1 | 2024 | 20 | 0.060 |
Why?
| Education, Medical, Graduate | 1 | 2009 | 438 | 0.060 |
Why?
| Natriuretic Peptide, Brain | 1 | 2024 | 99 | 0.060 |
Why?
| Genotype | 2 | 2020 | 1839 | 0.050 |
Why?
| Sarcoplasmic Reticulum | 1 | 2023 | 45 | 0.050 |
Why?
| Troponin | 1 | 2023 | 50 | 0.050 |
Why?
| Cytokines | 1 | 2011 | 2017 | 0.050 |
Why?
| Travel | 1 | 2023 | 122 | 0.050 |
Why?
| Cross-Sectional Studies | 3 | 2020 | 5066 | 0.050 |
Why?
| Practice Patterns, Physicians' | 1 | 2011 | 1266 | 0.050 |
Why?
| Histone Deacetylase 6 | 1 | 2022 | 17 | 0.050 |
Why?
| Disulfides | 1 | 2022 | 97 | 0.050 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2022 | 151 | 0.050 |
Why?
| Catecholamines | 1 | 2022 | 97 | 0.050 |
Why?
| Echocardiography, Doppler, Color | 1 | 2002 | 37 | 0.050 |
Why?
| RNA Splicing Factors | 1 | 2022 | 52 | 0.050 |
Why?
| Death, Sudden, Cardiac | 1 | 2023 | 179 | 0.050 |
Why?
| Rats, Sprague-Dawley | 2 | 2018 | 2406 | 0.050 |
Why?
| Calcium Channels | 1 | 2022 | 164 | 0.050 |
Why?
| Signal Transduction | 3 | 2021 | 4925 | 0.050 |
Why?
| Adolescent | 4 | 2019 | 20393 | 0.050 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2022 | 315 | 0.050 |
Why?
| Valsalva Maneuver | 1 | 2021 | 8 | 0.050 |
Why?
| Signal Processing, Computer-Assisted | 1 | 2002 | 144 | 0.050 |
Why?
| Prevalence | 2 | 2018 | 2564 | 0.040 |
Why?
| Anaerobic Threshold | 1 | 2021 | 28 | 0.040 |
Why?
| Phenylephrine | 1 | 2021 | 75 | 0.040 |
Why?
| Diagnostic Techniques, Cardiovascular | 1 | 2020 | 11 | 0.040 |
Why?
| Graft Survival | 1 | 2023 | 512 | 0.040 |
Why?
| Pharmacogenomic Testing | 1 | 2021 | 61 | 0.040 |
Why?
| Chronic Disease | 2 | 2017 | 1720 | 0.040 |
Why?
| Cardiomegaly | 1 | 2022 | 172 | 0.040 |
Why?
| Antibiotics, Antineoplastic | 1 | 2021 | 123 | 0.040 |
Why?
| Protein Isoforms | 1 | 2022 | 391 | 0.040 |
Why?
| Survival Rate | 1 | 2025 | 1877 | 0.040 |
Why?
| Culture Media | 1 | 2021 | 162 | 0.040 |
Why?
| Mice, Inbred C57BL | 2 | 2022 | 5440 | 0.040 |
Why?
| Cytomegalovirus | 1 | 2021 | 154 | 0.040 |
Why?
| Heart Valve Diseases | 1 | 2002 | 152 | 0.040 |
Why?
| HEK293 Cells | 1 | 2023 | 697 | 0.040 |
Why?
| Seizures | 1 | 2023 | 402 | 0.040 |
Why?
| Fellowships and Scholarships | 1 | 2023 | 273 | 0.040 |
Why?
| Heart Function Tests | 1 | 2020 | 59 | 0.040 |
Why?
| Electric Countershock | 1 | 2020 | 105 | 0.040 |
Why?
| Cardiac Resynchronization Therapy | 1 | 2020 | 45 | 0.040 |
Why?
| Adenosine Triphosphate | 1 | 2022 | 480 | 0.040 |
Why?
| Norepinephrine | 1 | 2021 | 210 | 0.040 |
Why?
| Acylation | 1 | 2019 | 28 | 0.040 |
Why?
| Aged, 80 and over | 2 | 2024 | 7086 | 0.040 |
Why?
| Reactive Oxygen Species | 1 | 2022 | 596 | 0.040 |
Why?
| Program Evaluation | 2 | 2017 | 875 | 0.040 |
Why?
| Molecular Diagnostic Techniques | 1 | 2020 | 98 | 0.040 |
Why?
| Gene Silencing | 1 | 2020 | 190 | 0.040 |
Why?
| Principal Component Analysis | 1 | 2020 | 189 | 0.040 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 442 | 0.040 |
Why?
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 83 | 0.040 |
Why?
| Methylation | 1 | 2019 | 230 | 0.040 |
Why?
| Internship and Residency | 1 | 2009 | 1053 | 0.040 |
Why?
| Coronary Angiography | 1 | 2020 | 306 | 0.040 |
Why?
| Cluster Analysis | 1 | 2020 | 482 | 0.040 |
Why?
| Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.040 |
Why?
| Disease Susceptibility | 1 | 2020 | 333 | 0.040 |
Why?
| Fatty Acids | 1 | 2021 | 427 | 0.040 |
Why?
| Oxygen Consumption | 1 | 2021 | 672 | 0.040 |
Why?
| Hydroxamic Acids | 1 | 2018 | 88 | 0.040 |
Why?
| Zebrafish | 1 | 2022 | 458 | 0.040 |
Why?
| Fibroblasts | 1 | 2022 | 948 | 0.040 |
Why?
| Collagen | 1 | 2020 | 434 | 0.030 |
Why?
| Hyperplasia | 1 | 2018 | 171 | 0.030 |
Why?
| Myosins | 1 | 2018 | 133 | 0.030 |
Why?
| Lysine | 1 | 2019 | 286 | 0.030 |
Why?
| Fluorine Radioisotopes | 1 | 2017 | 11 | 0.030 |
Why?
| Alleles | 1 | 2020 | 845 | 0.030 |
Why?
| Autoradiography | 1 | 2017 | 73 | 0.030 |
Why?
| Surveys and Questionnaires | 2 | 2021 | 5406 | 0.030 |
Why?
| Diphenoxylate | 1 | 2016 | 5 | 0.030 |
Why?
| Patient Reported Outcome Measures | 1 | 2020 | 373 | 0.030 |
Why?
| Atropine | 1 | 2016 | 24 | 0.030 |
Why?
| Loperamide | 1 | 2016 | 11 | 0.030 |
Why?
| Antidiarrheals | 1 | 2016 | 15 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2020 | 384 | 0.030 |
Why?
| Papio | 1 | 2017 | 91 | 0.030 |
Why?
| Tissue Donors | 1 | 2019 | 391 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2018 | 387 | 0.030 |
Why?
| Organ Culture Techniques | 1 | 2017 | 154 | 0.030 |
Why?
| Circadian Rhythm | 1 | 2020 | 413 | 0.030 |
Why?
| Transcription Elongation, Genetic | 1 | 2016 | 22 | 0.030 |
Why?
| Transcription Initiation Site | 1 | 2016 | 43 | 0.030 |
Why?
| Gastrointestinal Agents | 1 | 2016 | 61 | 0.030 |
Why?
| Radiopharmaceuticals | 1 | 2017 | 168 | 0.030 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2018 | 209 | 0.030 |
Why?
| Disease Management | 1 | 2020 | 589 | 0.030 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2021 | 821 | 0.030 |
Why?
| Referral and Consultation | 1 | 2021 | 732 | 0.030 |
Why?
| 3' Untranslated Regions | 1 | 2016 | 138 | 0.030 |
Why?
| Actins | 1 | 2018 | 411 | 0.030 |
Why?
| Drug Combinations | 1 | 2016 | 330 | 0.030 |
Why?
| Acetylation | 1 | 2016 | 246 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2018 | 779 | 0.030 |
Why?
| Magnetic Resonance Imaging | 2 | 2020 | 3408 | 0.030 |
Why?
| Feasibility Studies | 1 | 2019 | 868 | 0.030 |
Why?
| Survival Analysis | 1 | 2018 | 1274 | 0.030 |
Why?
| Self-Management | 1 | 2017 | 163 | 0.030 |
Why?
| Cell Line | 1 | 2021 | 2781 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 487 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2020 | 1952 | 0.030 |
Why?
| Muscle, Smooth, Vascular | 1 | 2018 | 443 | 0.030 |
Why?
| Mental Health | 1 | 2021 | 686 | 0.030 |
Why?
| Factor X | 1 | 2014 | 25 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2020 | 2119 | 0.030 |
Why?
| Cobalt | 1 | 2014 | 50 | 0.030 |
Why?
| Reoperation | 1 | 2016 | 545 | 0.030 |
Why?
| Polymerase Chain Reaction | 1 | 2016 | 1038 | 0.030 |
Why?
| Warfarin | 1 | 2014 | 147 | 0.030 |
Why?
| Mass Screening | 1 | 2021 | 1149 | 0.030 |
Why?
| Models, Biological | 1 | 2021 | 1722 | 0.030 |
Why?
| Action Potentials | 1 | 2017 | 486 | 0.030 |
Why?
| Amino Acids, Aromatic | 1 | 2013 | 8 | 0.030 |
Why?
| Self Report | 1 | 2017 | 799 | 0.030 |
Why?
| Child, Preschool | 2 | 2019 | 10517 | 0.030 |
Why?
| RNA Polymerase II | 1 | 2016 | 317 | 0.030 |
Why?
| Proteomics | 1 | 2019 | 1062 | 0.030 |
Why?
| Creatine | 1 | 2013 | 58 | 0.030 |
Why?
| Heparin | 1 | 2014 | 253 | 0.030 |
Why?
| Glutamine | 1 | 2013 | 99 | 0.030 |
Why?
| Algorithms | 1 | 2020 | 1622 | 0.020 |
Why?
| Chromatin | 1 | 2016 | 479 | 0.020 |
Why?
| Cell Cycle Proteins | 1 | 2016 | 586 | 0.020 |
Why?
| Antibodies | 1 | 2014 | 398 | 0.020 |
Why?
| Alanine | 1 | 2013 | 142 | 0.020 |
Why?
| Depression | 1 | 2021 | 1307 | 0.020 |
Why?
| RNA, Messenger | 1 | 2020 | 2708 | 0.020 |
Why?
| Medication Adherence | 1 | 2017 | 558 | 0.020 |
Why?
| Dyspnea | 1 | 2014 | 242 | 0.020 |
Why?
| Fatigue | 1 | 2014 | 318 | 0.020 |
Why?
| Endothelium, Vascular | 1 | 2018 | 901 | 0.020 |
Why?
| Phenotype | 1 | 2020 | 3076 | 0.020 |
Why?
| Lactic Acid | 1 | 2013 | 303 | 0.020 |
Why?
| Patient Discharge | 1 | 2016 | 857 | 0.020 |
Why?
| Sex Factors | 1 | 2015 | 1968 | 0.020 |
Why?
| Catheter Ablation | 1 | 2012 | 335 | 0.020 |
Why?
| Age Factors | 1 | 2015 | 3144 | 0.020 |
Why?
| Child | 2 | 2019 | 20883 | 0.020 |
Why?
| Glucose | 1 | 2013 | 1003 | 0.020 |
Why?
| Focus Groups | 1 | 2009 | 453 | 0.020 |
Why?
| Glomerular Filtration Rate | 1 | 2009 | 711 | 0.020 |
Why?
| Infant | 1 | 2015 | 9024 | 0.010 |
Why?
| Clinical Competence | 1 | 2009 | 1017 | 0.010 |
Why?
| Observer Variation | 1 | 2002 | 315 | 0.010 |
Why?
|
|
Ambardekar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|